DOI:

Percutaneous closure of paravalvular aortic leaks with the Amplatzer Vascular Plug III ®, late clinical follow-up

Sandoval Berrocal J., Paulo M., Hernandez-Antolin R., Rodas C., Martin P., Dutary J., Fernandez-Viña F., Garcia Fernandez E.

Treatment and consequences of regurgitation during transcatheter valve therapies

Percutaneous closure of paravalvular aortic leaks with the Amplatzer Vascular Plug III ®, late clinical follow-up

Aims: Percutaneous closure of aortic paravalvular leaks (APL) has been presented as an alternative to reoperation. Our objective was to describe our population undergoing percutaneous repair of APL with the Amplatzer Vascular Plug III® (AVP III) device and describe clinical events.

Methods and results: All patients were considered who underwent percutaneous repair of at least one APL where the AVP III device was used. Results are reported as medians and differences in chi-square. There were 12 patients aged 67±14 years. The number of aortic valve surgeries was 2.03±0.96. Interval time from the last surgery to percutaneous closure of the APL was 7.61±7.66 years. Nine patients had mechanical valve prosthesis, four patients also had a mechanical mitral valve and presented a mitral paravalvular leak. Clinical presentation: 30% had heart failure, 10% haemolytic anaemia and 60% both. The NYHA functional Class 3±0.58, haematocrit 28.7±4.9%, LDH 1,219±928 UI/L. Echocardiography: LVEF 60±9%; systolic PAP: 55±28 mmHg; numbers of APL 16; degree of regurgitation 3.2±0.8; EuroSCORE 14±4. In 13 procedures, 13 APL were attempted; the wire was crossed retrograde in 12 APL, an arterial venous loop was established in 4 patients where the delivery sheath was advanced anterograde. The procedure was successful in 11 patients and 11 APL with 1.09 AVP III devices implanted. Simultaneous mitral and aortic closure was accomplished in three patients. Functional outcome of the procedure decreased APL regurgitation in 1±0.8 grades. Periprocedural events: pacemaker one patient (the pacemaker electrode moved while making the arteriovenous loop), femoral pseudoaneurysm: one patient, and mortality one patient (he did not have AVP III deployed and died three days later of heart failure). Follow-up 642±397 days. Ninety-one per cent of patients with AVP III show improvement of functional class by at least 1 grade, NYHA functional Class at follow-up was 2±0.9 p=0.004, haematocrit 35±4.3% p=0.03, LDH 438±353 UI p=0.04 and APL regurgitation 1±1.1 p=0.01. Late clinical events: new intervention for moderate to severe residual APL regurgitation in two patients (one patient at surgery at 246 days and one patient with new percutaneous repair with new AVP III at 727 days). Hospitalisation for aortic regurgitation: two patients; late mortality in one patient at 831 days of coronary artery disease.

Conclusions: Percutaneous closure of APL using an AVP III device is safe with high rate of immediate procedural success. Patients presented late clinical improvement in both functional classes and haematocrits, and a significant decrease in aortic periprosthetic regurgitation.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

Clinical research

10.4244/EIJ-D-22-01110 Aug 7, 2023
Percutaneous paravalvular leak closure after transcatheter aortic valve implantation: the international PLUGinTAVI Registry
Flores-Umanzor E et al
free

IMAGE IN CARDIOLOGY

10.4244/EIJV11I2A43 Jun 19, 2015
Device embolisation after transcatheter paravalvular leak closure
Cruz-González I et al
free

10.4244/EIJV11I10A220 Feb 19, 2016
Accurate procedural assessment of AR – critical for successful TAVI
Kapadia S and Tuzcu ME
free
Trending articles
309.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
72.85

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved